Difficult to Treat: Do We Need a New Definition?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database.Intensive care medicine · 2025
   Observational
2. Empirical decision-making for antimicrobial therapy in critically ill patients.BJA education · 2023
   Review
3. Trends of Multidrug-Resistant Pathogens, Difficult to Treat Bloodstream Infections, and Antimicrobial Consumption at a Tertiary Care Center in Lebanon from 2015-2020: COVID-19 Aftermath.Antibiotics (Basel, Switzerland) · 2021
   Article
4. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.The Lancet. Infectious diseases · 2020
   Article
5. Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance.Antibiotics (Basel, Switzerland) · 2020
   Review
6. The Burden of Bloodstream Infections due toOpen forum infectious diseases · 2020
   Article
7. Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections.Open forum infectious diseases · 2019
   Article
8. Reply to Raoult and Rolain, and to Echols and Tillotson.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
   Article

Corrections and comments

• Commented on by
  Reply to Raoult and Rolain, and to Echols and Tillotson.2019
• Comment on
  Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as